Metastatic breast cancer is now a defining reality for about 155,000 to 170,000 women in the US, and globally it drives around 90% of breast cancer deaths while representing only about 30% of cases. What makes the picture especially complicated is how biology flips across subtypes and treatment history, from ER tumors and ESR1 resistance to HER2-low spread and TNBC patterns like TP53 and PD-L1. In this post, you will see how the most telling biomarkers and outcomes line up together, including when a single mutation or marker can change what comes next.
Key Takeaways
- Approximately 70% of metastatic breast cancers express estrogen receptor (ER).
- PIK3CA mutations occur in 40% of HR+/HER2- metastatic breast cancers.
- ESR1 mutations are found in 20-40% of HR+ MBC after prior endocrine therapy.
- Approximately 6-10% of women with breast cancer are diagnosed with de novo metastatic disease at initial presentation.
- In the US, an estimated 155,000-170,000 women are living with metastatic breast cancer as of recent estimates.
- Globally, metastatic breast cancer accounts for around 90% of breast cancer deaths despite representing 30% of cases.
- Approximately 40% of metastatic breast cancer patients experience severe fatigue.
- Bone pain affects 70% of patients with bone metastases in MBC.
- 50-60% of MBC patients report moderate to severe pain requiring opioids.
- Median overall survival for metastatic breast cancer has improved from 22 months in 1990s to 38 months currently.
- 5-year overall survival for metastatic breast cancer is 29% per SEER 2015-2021 data.
- For HR+/HER2- metastatic breast cancer, median OS is 48-60 months with modern therapies.
- Overall response rate (ORR) to first-line CDK4/6i + ET is 40-55% in HR+ MBC.
- In MONALEESA-2, ribociclib + letrozole achieved median PFS of 25.3 months vs 16.0 months placebo.
- Palbociclib + fulvestrant in PALOMA-3 showed ORR 19% vs 10% placebo.
Metastatic breast cancer affects hundreds of thousands of women, with key biomarkers guiding targeted treatment.
Related reading
01 · Category
Biomarkers and Subtypes27 stats
01
Approximately 70% of metastatic breast cancers express estrogen receptor (ER).
02
PIK3CA mutations occur in 40% of HR+/HER2- metastatic breast cancers.
03
ESR1 mutations are found in 20-40% of HR+ MBC after prior endocrine therapy.
04
BRCA1/2 germline mutations in 5-10% of all metastatic breast cancer patients.
05
PD-L1 expression (CPS ≥10) in 20-25% of triple-negative metastatic breast cancers.
06
HER2-low expression (IHC 1+ or 2+/ISH-) in 50-60% of metastatic breast cancers.
07
TP53 mutations in 80% of triple-negative metastatic breast cancers.
08
AKT1 mutations in 3-7% of HR+ metastatic breast cancers.
09
HER2 overexpression (IHC 3+) in 15% of metastatic breast cancers.
10
PTEN loss in 20-30% of metastatic breast cancers, associated with poor prognosis.
11
ctDNA ESR1 mutation detection predicts resistance in 30% pre-progression.
12
Ki-67 proliferation index >20% in 60% of HR+ MBC correlates with aggressiveness.
13
PDGFR overexpression in 40% of TNBC metastatic tumors.
14
FGFR1 amplification in 10-15% of HR+ metastatic breast cancers.
15
MSI-high status in <1% of metastatic breast cancers.
16
ERBB2 (HER2) amplification detected by NGS in 18% of MBC.
17
PALB2 mutations in 2-3% of unselected metastatic breast cancers.
18
RB1 loss in 20% of TNBC MBC, predicting CDK4/6i resistance.
19
Androgen receptor positivity in 50-80% of TNBC metastatic cases.
20
CTC count >5/7.5ml blood prognostic in 70% of MBC patients.
21
60% of metastatic breast cancers retain primary tumor subtype concordance.
22
CCND1 amplification in 15% HR+ MBC.
23
TMB-high (>10 mut/Mb) in 5% of metastatic breast cancers.
24
NF1 mutations in 10% of TNBC MBC.
25
Aromatase inhibitor resistance linked to ESR1 Y537S mutation in 15%.
26
30% of HR+ MBC show increased tumor mutational burden post-endocrine therapy.
27
MYC amplification in 25% of HER2+ metastatic breast cancers.
Interpretation
Biomarkers and Subtypes Interpretation
This landscape of metastatic breast cancer is a sobering testament to its cunning adaptability, where a majority initially cling to hormone receptors yet evolve a complex genetic arsenal of resistance and survival, revealing that our therapeutic battles must be fought on dozens of distinct molecular fronts.
02 · Category
Epidemiology29 stats
01
Approximately 6-10% of women with breast cancer are diagnosed with de novo metastatic disease at initial presentation.
02
In the US, an estimated 155,000-170,000 women are living with metastatic breast cancer as of recent estimates.
03
Globally, metastatic breast cancer accounts for around 90% of breast cancer deaths despite representing 30% of cases.
04
The incidence rate of metastatic breast cancer has remained stable at about 4-5 per 100,000 women annually in the US.
05
Among postmenopausal women with HR+/HER2- metastatic breast cancer, prevalence is highest in ages 65-74.
06
In Europe, about 1.2 million women live with metastatic breast cancer, representing 20-30% of all breast cancer patients.
07
De novo metastatic breast cancer comprises 3-6% of all new breast cancer diagnoses in population-based registries.
08
The 5-year relative survival rate for distant metastatic breast cancer is 30.4% based on SEER data 2014-2020.
09
In Asia, metastatic breast cancer incidence is rising by 2-3% annually due to aging populations.
10
Black women have a 1.5-fold higher risk of developing metastatic breast cancer compared to White women.
11
Approximately 70% of metastatic breast cancers are hormone receptor-positive (HR+).
12
HER2-positive metastatic breast cancer represents 15-20% of all metastatic cases.
13
Triple-negative metastatic breast cancer accounts for 10-15% of metastatic diagnoses.
14
Visceral metastases are present in 60-75% of patients at metastatic breast cancer diagnosis.
15
Bone is the most common site of metastasis, affecting 65-75% of metastatic breast cancer patients.
16
Liver metastases occur in 25-30% of metastatic breast cancer cases at diagnosis.
17
Brain metastases develop in 10-30% of metastatic breast cancer patients over disease course.
18
The median age at diagnosis of metastatic breast cancer is 63 years.
19
In low-income countries, up to 50% of breast cancers present as metastatic due to late detection.
20
Recurrent metastatic breast cancer after early-stage disease occurs in 20-30% of patients within 5-10 years.
21
The overall 5-year prevalence of metastatic breast cancer in the EU is approximately 500,000 women.
22
Young women under 40 represent 5-7% of metastatic breast cancer cases.
23
Male metastatic breast cancer cases are rare, comprising <1% of total metastatic breast cancers.
24
Inflammatory breast cancer metastasizes early, with 30% presenting as stage IV.
25
Median time from primary diagnosis to metastasis is 2.6-3.9 years for early-stage breast cancer.
26
In 2022, about 42,250 breast cancer deaths in the US were attributable to metastatic disease.
27
The global burden of metastatic breast cancer is projected to increase by 50% by 2040.
28
Oligometastatic breast cancer (≤5 sites) occurs in 10-15% of metastatic presentations.
29
The 10-year prevalence of women living with metastatic breast cancer in the US is over 100,000.
Interpretation
Epidemiology Interpretation
Metastatic breast cancer, while representing a minority of initial diagnoses, is the grim architect behind the overwhelming majority of breast cancer deaths, a sobering paradox where a smaller number unleashes an outsized devastation.
03 · Category
Quality of Life and Symptom Burden27 stats
01
Approximately 40% of metastatic breast cancer patients experience severe fatigue.
02
Bone pain affects 70% of patients with bone metastases in MBC.
03
50-60% of MBC patients report moderate to severe pain requiring opioids.
04
Dyspnea occurs in 40% of patients with lung metastases.
05
Neuropathic pain from chemotherapy affects 30-50% of MBC patients.
06
Depression prevalence is 25-40% in metastatic breast cancer population.
07
65% of MBC patients experience weight loss >5% body weight annually.
08
Insomnia reported by 55% of women with metastatic breast cancer.
09
Nausea/vomiting impacts 35% during systemic therapy for MBC.
10
Cognitive impairment ("chemo brain") in 75% of long-term MBC survivors.
11
Sexual dysfunction affects 80% of premenopausal MBC patients on ET.
12
45% of MBC patients have anemia (Hb<10g/dL) contributing to fatigue.
13
Edema/lymphedema in 30% of patients with axillary involvement.
14
Hot flashes in 70% of patients on tamoxifen or AIs for MBC.
15
Constipation from opioids in 50% of pain-managed MBC patients.
16
20-30% of brain met patients experience seizures impacting QOL.
17
FACT-B QOL score declines by 10-15 points after progression.
18
Financial toxicity affects 60% of MBC patients with high out-of-pocket costs.
19
Social isolation reported by 40% of metastatic breast cancer patients.
20
Diarrhea grade 3+ in 10-20% on CDK4/6 inhibitors.
21
55% of MBC patients require palliative care within first year.
22
Appetite loss in 50% of patients with liver metastases.
23
Skin rash from TKIs affects 40% of HER2-targeted therapy patients.
24
Mean EQ-5D score 0.70 in MBC vs 0.85 general population.
25
35% of survivors report body image distress post-mastectomy in MBC.
26
Hypercalcemia symptomatic in 15% of bone met patients.
27
25% experience caregiver burden in family of MBC patients.
Interpretation
Quality of Life and Symptom Burden Interpretation
While metastatic breast cancer is often framed as a battle to be won, these statistics paint the sobering portrait of a relentless siege where managing the collateral damage—from bone pain and chemo brain to financial ruin and isolation—becomes the daily reality for survival.
More related reading
04 · Category
Survival and Prognosis24 stats
01
Median overall survival for metastatic breast cancer has improved from 22 months in 1990s to 38 months currently.
02
5-year overall survival for metastatic breast cancer is 29% per SEER 2015-2021 data.
03
For HR+/HER2- metastatic breast cancer, median OS is 48-60 months with modern therapies.
04
Triple-negative metastatic breast cancer has a median OS of 12-18 months.
05
HER2+ metastatic breast cancer median OS exceeds 5 years with trastuzumab-based therapy.
06
Patients with bone-only metastatic disease have median OS of 52 months vs 28 months for visceral.
07
Brain metastases reduce median OS to 6-15 months in metastatic breast cancer.
08
De novo metastatic breast cancer has 20-30% better OS than recurrent metastatic disease.
09
10-year OS for metastatic breast cancer is approximately 15-20% in recent cohorts.
10
Oligometastatic disease treated aggressively achieves 5-year OS of 40-50%.
11
In elderly (>75 years) metastatic breast cancer patients, median OS is 24 months.
12
Black patients with metastatic breast cancer have 15-20% worse OS than White patients.
13
Median PFS for first-line therapy in MBC is 8-12 months across subtypes.
14
Patients with ER+/PR+/HER2- MBC have 5-year OS of 34% vs 12% for TNBC.
15
Visceral crisis at diagnosis predicts median OS <12 months.
16
With CDK4/6 inhibitors, median OS in HR+ MBC reaches 60+ months in some trials.
17
Historical median OS for untreated MBC was 6-12 months pre-1980s.
18
2-year survival rate for metastatic breast cancer is 75% overall.
19
Liver-dominant metastases confer median OS of 20 months.
20
In young (<40) MBC patients, 5-year OS is 25-30%.
21
Performance status ECOG 0-1 predicts median OS >36 months vs <12 for ECOG 3-4.
22
Number of metastatic sites >3 reduces median OS by 50%.
23
Prior adjuvant endocrine therapy duration >5 years worsens MBC OS.
24
In MONARCH-3 trial, abemaciclib improved median OS to 66.8 months in HR+ MBC.
Interpretation
Survival and Prognosis Interpretation
While the grim reality of metastatic breast cancer persists, with survival varying dramatically by subtype, race, and disease burden, the collective march from a near-universal death sentence to scenarios where some patients now measure their survival in many years—even decades—is a testament to scientific progress that remains fiercely urgent and profoundly unequal.
05 · Category
Treatment Efficacy25 stats
01
Overall response rate (ORR) to first-line CDK4/6i + ET is 40-55% in HR+ MBC.
02
In MONALEESA-2, ribociclib + letrozole achieved median PFS of 25.3 months vs 16.0 months placebo.
03
Palbociclib + fulvestrant in PALOMA-3 showed ORR 19% vs 10% placebo.
04
In DESTINY-Breast03, trastuzumab deruxtecan PFS 28.8 months vs 6.8 months T-DM1.
05
Sacituzumab govitecan in TNBC MBC (ASCENT) ORR 35% vs 5% chemo.
06
Everolimus + exemestane (BOLERO-2) PFS 10.6 vs 4.1 months.
07
In EMPOWER-Lung3 but for breast analog, durvalumab + chemo in PD-L1+ MBC PFS 10.6 months.
08
Pertuzumab + trastuzumab + docetaxel ORR 80% in CLEOPATRA first-line HER2+.
09
Abemaciclib + ET in MONARCH-2 median PFS 16.4 vs 9.3 months.
10
Capivasertib + fulvestrant in PIK3CA-mutated MBC PFS 7.3 vs 3.1 months (CAPItello-291).
11
Tucatinib + trastuzumab + capecitabine OS HR 0.73 in HER2+ brain mets (HER2CLIMB).
12
In KEYNOTE-355, pembrolizumab + chemo ORR 53% vs 40% chemo in TNBC PD-L1 CPS≥10.
13
Elacestrant vs SOC in ESR1-mutated MBC PFS 3.8 vs 1.9 months (EMERALD).
14
Alpelisib + fulvestrant in PIK3CA-mut PFS 11 vs 5.7 months (SOLAR-1).
15
Neratinib post-adjuvant in high-risk HER2+ reduces MBC recurrence by 35% (ExteNET).
16
In ASCENT trial, sacituzumab govitecan median OS 12.1 vs 6.7 months in pretreated TNBC MBC.
17
Ribociclib + ET OS benefit 12+ months in MONALEESA-7 advanced HR+ MBC.
18
T-DXd ORR 79% in HER2-low MBC (DESTINY-Breast04).
19
Camizestrant + CDK4/6i DCR 85% in SERENA-2 phase 2.
20
In TNBC, PARP inhibitors in BRCA+ show ORR 21% with talazoparib (EMBRACA).
21
Fulvestrant 500mg monotherapy PFS 6.5 months in CONFIRM trial.
22
Ibrance (palbociclib) + letrozole ORR 55% first-line HR+.
23
In CLEOPATRA, pertuzumab combo OS 56.5 vs 40.8 months.
24
Datopotamab deruxtecan ORR 52.4% in TROPION-Breast01.
25
Olaparib + chemo in OlympiA reduces distant recurrence by 42% post-neoadjuvant TNBC.
Interpretation
Treatment Efficacy Interpretation
The sheer variety of targeted weapons now in our arsenal means that for nearly every subtype of metastatic breast cancer, there is a meaningful treatment that can significantly slow its march, turning what was once a rapid decline into a series of hard-fought and prolonged battles.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Aisha Okonkwo. (2026, February 13). Metastatic Breast Cancer Statistics. Gitnux. https://gitnux.org/metastatic-breast-cancer-statistics
MLA
Aisha Okonkwo. "Metastatic Breast Cancer Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/metastatic-breast-cancer-statistics.
Chicago
Aisha Okonkwo. 2026. "Metastatic Breast Cancer Statistics." Gitnux. https://gitnux.org/metastatic-breast-cancer-statistics.
Sources & references
15 datasets cited across this report · attribution is report-level